CClinicalTrials.gg
RecruitingNCT03761121Updated Dec 12, 2025

Developing Fast Pediatric Imaging

An interventional study of Wave-CAIPI in Pediatric Low-grade Gliomas, sponsored by Boston Children's Hospital. Recruiting at 3 sites in United States. Open to participants aged 0 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Apr 2019; still recruiting 7 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
0 Years and older
Sex
All
01

Study summary

This research study is evaluating the investigational software for magnetic resonance imaging (MRI) systems and techniques to process magnetic resonance (MR) images

Read the detailed description

The purpose of the study is to develop new technologies for MRI systems. The new technologies should improve MRI capabilities in terms of how sensitive, specific, and efficient they are. The overall goal is to get better measurements of the brain tumor tissue(s).

In this research study, the investigators want to learn more about investigational software and about techniques to process MR images. The testing of investigational software will allow the investigators to improve the image quality. As part of the testing process, the investigators will collect more MR images of the brain, and improve current image reconstruction methods. This will allow a more precise analysis of MR images and potentially better assessment of the brain tumor tissue volume.

02

Conditions studied

  • Pediatric Low-grade Gliomas

Keywords

  • Neuro Oncology
03

In context

Lead sponsor

Boston Children's Hospital is the lead sponsor of 598 studies on the registry; 151 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Infants, children and adults who have been diagnosed with Low Grade Glioma
  • Healthy volunteers - Children from age 0 to adults with no upper age limit or;
  • Diagnosed with LGG and being treated at DFCI;

Exclusion criteria

Exclusion Criteria:

  • Electrical implants such as cardiac pacemakers or perfusion pumps;
  • Ferromagnetic implants such as aneurysm clips, surgical clips, prosthesis, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants;
  • Ferromagnetic objects such as jewelry or metal clips;
  • Women of childbearing age who are seeking to become pregnant, who are breastfeeding, or who suspect they may be pregnant;
  • Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions;
  • Any greater than normal potential for cardiac arrest
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Primary Testing Group

    * This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes * Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution * Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution

    Other: Wave-CAIPI

  • Experimental
    Software Testing Group

    * Participants will receive hour research-only scan * Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution * Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution

    Other: Wave-CAIPI

Interventions

  • OtherWave-CAIPI

    "wave-CAIPI" technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding

06

What researchers measure

Primary outcomes

  1. Wave-CAIPI validation

    The outcome measure for this project will be that the rapid scan from Wave-CAIPI can provide equivalent diagnostic quality to that of standard clinical acquisitions which is performed at much slower speed. This will be assess using visual qualitative assessment by experienced radiologists on the project.

    Time frame: 2 years

07

Study locations

3 of 3 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02214, United States
    Recruiting
  • Boston Children Hospital
    Boston, Massachusetts 02215, United States
    • Susan N Chi, MD · Contact · schi@partners.org · 617-632-3000
    • Susan N Chi, MD · Principal investigator
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    • Susan N Chi, MD · Contact · schi@partners.org · 617-632-3000
    • Susan N Chi, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor- Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03761121
Lead sponsor
Boston Children's Hospital
Collaborators
National Institute for Biomedical Imaging and Bioengineering (NIBIB), Dana-Farber Cancer Institute
Responsible party
Ellen Grant (Principal Investigator, Boston Children's Hospital) — Principal investigator
First posted
Dec 3, 2018
Start date
Apr 15, 2019
Primary completion
Sep 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Dec 12, 2025

Study contacts

Kawin Setsompop, PhD
Contact
kawin@nmr.mgh.harvard.edu
617-669-6640
Kawin Setsompop, PhD
principal investigator · Boston Children Hospital/ Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion